China
· Delayed Price · Currency is CNY Jiangsu Sinopep-Allsino Biopharmaceutical Statistics
Total Valuation
Jiangsu Sinopep-Allsino Biopharmaceutical has a market cap or net worth of CNY 13.10 billion. The enterprise value is 13.53 billion.
| Market Cap | 13.10B |
| Enterprise Value | 13.53B |
Important Dates
The next estimated earnings date is Monday, October 21, 2024.
| Earnings Date | Oct 21, 2024 |
| Ex-Dividend Date | Sep 10, 2024 |
Share Statistics
Jiangsu Sinopep-Allsino Biopharmaceutical has 219.78 million shares outstanding. The number of shares has increased by 7.13% in one year.
| Shares Outstanding | 219.78M |
| Shares Change (YoY) | +7.13% |
| Shares Change (QoQ) | +3.46% |
| Owned by Insiders (%) | 15.70% |
| Owned by Institutions (%) | 24.84% |
| Float | 124.36M |
Valuation Ratios
The trailing PE ratio is 38.02 and the forward PE ratio is 31.00.
| PE Ratio | 38.02 |
| Forward PE | 31.00 |
| PS Ratio | 8.83 |
| PB Ratio | 5.35 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.06, with an EV/FCF ratio of -37.03.
| EV / Earnings | 38.85 |
| EV / Sales | 9.24 |
| EV / EBITDA | 24.06 |
| EV / EBIT | 34.20 |
| EV / FCF | -37.03 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.47.
| Current Ratio | 1.37 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.47 |
| Debt / EBITDA | 2.04 |
| Debt / FCF | -3.14 |
| Interest Coverage | 17.26 |
Financial Efficiency
Return on equity (ROE) is 16.45% and return on invested capital (ROIC) is 8.34%.
| Return on Equity (ROE) | 16.45% |
| Return on Assets (ROA) | 7.46% |
| Return on Capital (ROIC) | 8.34% |
| Revenue Per Employee | 823,083 |
| Profits Per Employee | 195,753 |
| Employee Count | 1,545 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 1.41 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +88.10% in the last 52 weeks. The beta is 0.44, so Jiangsu Sinopep-Allsino Biopharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +88.10% |
| 50-Day Moving Average | 60.83 |
| 200-Day Moving Average | 55.93 |
| Relative Strength Index (RSI) | 52.52 |
| Average Volume (20 Days) | 4,962,621 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jiangsu Sinopep-Allsino Biopharmaceutical had revenue of CNY 1.46 billion and earned 348.25 million in profits. Earnings per share was 1.57.
| Revenue | 1.46B |
| Gross Profit | 919.77M |
| Operating Income | 395.62M |
| Pretax Income | 382.21M |
| Net Income | 348.25M |
| EBITDA | 557.35M |
| EBIT | 395.62M |
| Earnings Per Share (EPS) | 1.57 |
Balance Sheet
The company has 740.22 million in cash and 1.15 billion in debt, giving a net cash position of -408.08 million or -1.86 per share.
| Cash & Cash Equivalents | 740.22M |
| Total Debt | 1.15B |
| Net Cash | -408.08M |
| Net Cash Per Share | -1.86 |
| Equity (Book Value) | 2.42B |
| Book Value Per Share | 11.14 |
| Working Capital | 468.21M |
Cash Flow
In the last 12 months, operating cash flow was 375.87 million and capital expenditures -741.30 million, giving a free cash flow of -365.43 million.
| Operating Cash Flow | 375.87M |
| Capital Expenditures | -741.30M |
| Free Cash Flow | -365.43M |
| FCF Per Share | -1.66 |
Margins
Gross margin is 62.81%, with operating and profit margins of 27.02% and 23.78%.
| Gross Margin | 62.81% |
| Operating Margin | 27.02% |
| Pretax Margin | 26.10% |
| Profit Margin | 23.78% |
| EBITDA Margin | 38.06% |
| EBIT Margin | 27.02% |
| FCF Margin | -24.96% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.32%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.32% |
| Dividend Growth (YoY) | 150.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 30.10% |
| Buyback Yield | -7.13% |
| Shareholder Yield | -6.81% |
| Earnings Yield | 2.63% |
| FCF Yield | -2.79% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Jiangsu Sinopep-Allsino Biopharmaceutical has an Altman Z-Score of 4.7.
| Altman Z-Score | 4.7 |
| Piotroski F-Score | n/a |